期刊文献+

原发性骨髓纤维化的诊断和治疗进展 被引量:4

原文传递
导出
摘要 原发性骨髓纤维化( primary myelofibrosis, PMF) 是一种造血干细胞克隆性增殖所致的骨髓增殖性肿瘤(myeloproliferative neoplasm, MPN),BCR—ABL阴性MPN分子发病机制的新发现为这类疾病的遗传学分类及分子诊断带来了希望,在此基础上2008年WHO对PMF的诊断标准进行了新的修改。PMF的治疗多是姑息性的,异基因干细胞移植(allogeneic stem cell transplantation,allo-SCT)为根治骨髓纤维化的唯一方法,近年来针对病因的研究使得分子靶向治疗和其他新药的研发成为可能。
出处 《国际输血及血液学杂志》 CAS 2010年第1期40-44,共5页 International Journal of Blood Transfusion and Hematology
  • 相关文献

参考文献1

二级参考文献9

  • 1莫汉有,蒋静子,覃泱,莫东华,周润华.原发性骨髓纤维化患者血管内皮生长因子水平变化与反应停的干预[J].中国临床康复,2006,10(33):59-61. 被引量:1
  • 2MARTYER M C,ROMQUIN N, LE BOUSSE-KERDILES M C, et al. Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis[J]. Br J Haematol, 1994,88 : 9 - 16.
  • 3BOCK O, LOCK G, BUSCHE G, et al. Aberrant expression of platelet-drived growth factor (PDGF)and latelet-drived growth factor receptor-alpha is associated with advanced bone marrow fibrosis in idiopathic myelofibrosis[J]. Haematol, 2005,90 : 133-134.
  • 4MESA R A,EILLIOLL M A,SCHROEDER G,et al. Durable response to thalidomide based drug therapy for myelofibrosis[J]. Mayo Clin Proc, 2004,79 : 883 - 889.
  • 5SPETS H, STROMBERG T, GEORGII HEMMING P,et al. Expression of the bcl-2 family of pro and anti apoptosis genes in multiple myeloma and normal plasma cells: regulation during interleukin 6 (IL- 6) induced growth and survival[J]. Eur J Haematol,2002, 69:76-89.
  • 6MESA R A, STEENSMA D P, PARDANANI A, et al. A phase 2 trial of combination low-dose Thalidomide and prednisone for the treatment of myelofibrosis with myeloed metaplasia[J]. Blood, 2003,101 : 2534 - 2541.
  • 7WU W Z,SUN H C,SHEN Y F,et al. Interferon alpha 2a down-regulates VEGF expression through P13 kinase and MAP kinase signaling pathways [J]. J Cancer Res Clin Oncol,2005,131 : 169- 178.
  • 8张海燕,李长龙.帕米磷酸二钠联合沙立度胺对平台期多发性骨髓瘤患者血清VEGF及IL-6的影响及临床意义[J].临床血液学杂志,2007,20(5):302-303. 被引量:1
  • 9尹延珂,王慧君,张莉,周康,李洪强,杨栋林,张凤奎.小剂量沙利度胺联合泼尼松治疗慢性特发性骨髓纤维化11例临床疗效观察[J].中华血液学杂志,2007,28(11):766-767. 被引量:3

同被引文献39

  • 1金玉青,洪远林,李建蕊,李曦,王晓晓,吕光华.川芎的化学成分及药理作用研究进展[J].中药与临床,2013,4(3):44-48. 被引量:382
  • 2潘磊,陈培丰.清热解毒中药抗肿瘤作用机理研究进展[J].中华中医药学刊,2007,25(3):569-571. 被引量:65
  • 3Thiele J, Kvasnicka HM, Facchetti F,et al. European consensus on grading bone marrow fibrosis and assessment of cellularity [ J ]. Haematologica,2005,90 : 1128 - 1132.
  • 4Lazzarino M, Morra E, Castello A, et al. Myelofibrosis in chronic granulocytic leukaemia: clinicopathologic correlations and prog- nostic significance [ J ]. Br J Haematol, 1986,64 (2) :227 - 240.
  • 5Marisavljevic D, Rolovic Z, Cemerikic V, et al. Myelofibrosis in pri- mary myelodysplastic syndromes: clinical and biological signifi- cance [ J ]. Med Onco1,2004,21 (4) :325 - 331.
  • 6Imbert M, Ngnyen D, Sultan C. Myelodysplastic syndromes (MDS)and acutemyeloid leukemias (AML) with myelofibrosis [ J ]. Leuk Res,1992,16(1) :51 -54.
  • 7McCarthy DM. Annotation. Fibrosis of the bone marrow: content and causes[J]. Br J Haematol,1985 ,59 :1 -7.
  • 8胡亚美 江载芳.诸福棠实用儿科学7版[M].北京:人民卫生出版社,2002.441.
  • 9Thiele J,Kvasnicka HM,Facchetti F,et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica, 2005, 90:1128-1132.
  • 10Lazzarino M, Morra E, Castello A, et al. Myelofibrosis in chronicgranuloeytic leukaemia: clinieopathologic correlations and prognostic significance. Br J Haematol, 1986, 64:227-240.

引证文献4

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部